ArticleNephrology (Carlton, Vic.)2026
Association Between Tolvaptan Exposure and Venous Thromboembolism Risk in ADPKD: A Real-World Propensity-Matched EHR Study.
Article in Nephrology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimVenous thromboembolism (VTE) has increasingly been reported in autosomal dominant polycystic kidney disease (ADPKD), although the mechanisms underlying this association remain incompletely understood. Whether tolvaptan exposure influences VTE risk in ADPKD has not been well studied.
methodsWe performed a retrospective cohort study using the TriNetX Global Collaborative Network, including adults with ADPKD (ICD-10-CM Q61.2) from 2000 to 2025. Patients with inherited thrombophilia or prothrombin G20210A mutation were excluded. Propensity score matching (1:1) was conducted across 24 covariates to balance demographics, comorbidities, medications, and laboratory data. Exposure was analysed as a fixed treatment variable defined at cohort entry. Primary outcomes were VTE incidence, all-cause mortality, and use of antithrombotic medications.
resultsAmong 39 180 adults with ADPKD, 1338 received tolvaptan therapy, whereas 37 362 were without tolvaptan. After 1:1 propensity score matching, 1333 matched pairs were analysed. Tolvaptan exposure was associated with lower risks of VTE (2.1% vs. 3.9%; RR 0.538, 95% CI 0.342-0.847; p = 0.006) and all-cause mortality (1.28% vs. 3.9%; RR 0.327, 95% CI 0.190-0.562; p < 0.001). Lower utilisation of warfarin, aspirin, DOAC, heparin, or enoxaparin was observed (14.8% vs. 21.4%; RR 0.689, 95% CI 0.572-0.830; p < 0.001). Subgroup analyses demonstrated generally consistent directional associations across several demographic categories, although some subgroup analyses were limited by low event counts.
conclusionIn this large propensity-matched real-world cohort, tolvaptan exposure was associated with lower risks of VTE and mortality among patients with ADPKD. Given the retrospective observational design and the possibility of residual confounding, these findings should be interpreted as associative and hypothesis-generating rather than causal. Further prospective studies incorporating imaging-based measures of disease severity are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.